KEYNOTE-061
Regimen
- Experimental
- pembrolizumab 200 mg Q3W
- Control
- paclitaxel
Population
Advanced G/GEJ adenocarcinoma with PD-L1 CPS>=1 progressing after first-line platinum/fluoropyrimidine
Key finding
CPS>=1 mOS 9.1 vs 8.3 mo (HR 0.82, 95% CI 0.66-1.03, p=0.0421 NS, NEGATIVE); CPS>=10 signal of benefit; grade>=3 TRAE 14% vs 35%
Source: PMID 29880231
Timeline
Guideline citations
- NCCN GASTRIC (p.45)
- CSCO GASTRIC 2025 (p.33)⚠️ OCR source